Slide 1: A Regenerative Medicine Company
A Regenerative Medicine Company Stem cell therapies addressing life threatening conditions in the most vulnerable populations - children and the elderly Investor Presentation Nasdaq (LGVN) │ AUGUST 2026
Slide 2: Forward Looking Statements
Forward Looking Statements Forward Looking Statements Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectat
Slide 3: Corporate Overview
Corporate Overview Corporate Overview
Slide 4: Corporate Overview: Repositioning LGVN for Long-Term Growth
Corporate Overview: Repositioning LGVN for Long-Term Growth Strategic Leadership: Led by newly appointed CEO Steve Willard • Pipeline-in-a-Product: Laromestrocel (Lomecel-B®) A first- (Feb 2026), a veteran with a proven record of achieving $1B+ in-class allogeneic cell therapy with five FDA expedite
Slide 5: Lead Indication: Pediatric Heart Failure (HLHS)
Lead Indication: Pediatric Heart Failure (HLHS) Lead Indication: Pediatric Heart Failure (HLHS) Hypoplastic Left Heart Syndrome ("HLHS"): Is a congenital heart birth defect that is a terminal orphan condition with no approved medicinal therapies. • Current Treatment Plan: The standard treatment for
Slide 6: Addressing Unmet Medical Needs of Chronic and Life-threatening Conditions
Addressing Unmet Medical Needs of Chronic and Life-threatening Conditions Addressing Unmet Medical Needs of Chronic and Life-threatening Conditions Hypoplastic Left Heart Pediatric Dilated Alzheimer’s Disease Aging-related Frailty Syndrome (HLHS) Cardiomyopathy (PDCM) (AD) (AF) • One of the most sev
Slide 7: Follow-on Indications: PDCM & AD
Follow-on Indications: PDCM AD Follow-on Indications: PDCM & AD Pediatric Dilated Cardiomyopathy (PDCM) Alzheimer’s Disease (AD) • Strategic Expansion: Leveraging the cardiac survival signal • Differentiated Data: Phase 2a trial showed positive results in brain from HLHS, the Company applied for and
Slide 8: Program Snapshot & Prioritization
Program Snapshot Prioritization Program Snapshot & Prioritization Program Path Forward Current Status Clinical Data Signal Corporate Priority FDA Designation Phase 1 demonstrated 100% September 2026 Priority Review Voucher HLHS License Deal Phase 2b 5-year transplant-free survival (P2b Top-line data
Slide 9: Strategic Value of the IP Portfolio
Strategic Value of the IP Portfolio Strategic Value of the IP Portfolio At a sub $50 M market cap, the market is assigning negative value to our operating assets, essentially treating 50+ issued patents as a zero-value line item. This creates a massive Value Gap compared to our IP-protected peers wh
Slide 10: Valuation Details
Valuation Details Valuation Details
Slide 11: Key Investor Takeaways
Key Investor Takeaways Key Investor Takeaways Public-market precedent exists for allogeneic cell therapy companies achieving $1B+ valuations prior to U.S. commercial revenue, particularly in rare and life-threatening indications. Capricor Therapeutics provides a relevant valuation and regulatory pre
Slide 12: Public Market Comparables
Public Market Comparables Public Market Comparables Metric Mesoblast Ltd Capricor Therapeutics Longeveron Inc. Ticker NASDAQ: MESO NASDAQ: CAPR NASDAQ: LGVN Market Capitalization* ~$1.5–2.5B ~$1.1–1.3B ~sub $50M (subject to market changes) Allogeneic mesenchymal stem Cell and exosome-based Allogenei
Slide 13: Public Market Comparables Value Inflection Point
Public Market Comparables Value Inflection Point Public Market Comparables Value Inflection Point Capricor Therapeutics (NASDAQ: CAPR) Valuation Prior Inflection Point Date Valuation After / Impact (Market Cap) Quiet Period: Stock traded in the $4.00 - $6.00 range with relatively low Pre-Phase 3 Res
Slide 14: Valuation Floor - Longeveron potential shot on goal for PRV
Valuation Floor - Longeveron potential shot on goal for PRV Valuation Floor - Longeveron potential shot on goal for PRV Underpinning Our Valuation Floor: ~$200M PRV Asset Alone Recent Voucher Sale Details • Pipeline-in-a-Product: laromestrocel is a first-in-class allogeneic cell therapy with five FD
Slide 15: Why LGVN? Why Now?
Why LGVN? Why Now? Why LGVN? Why Now? Strategic Investment Thesis: The Valuation Disconnect LGVN Near-Term Value Inflection Drivers • Key Investor Takeaways • $1B+ Valuation Precedent: Validated public-market peers (Capricor, Mesoblast) Milestone Indication Timing demonstrate that allogeneic cell th
Slide 16: Therapies for life-threatening, rare pediatric & chronic aging-related conditions
Therapies for life-threatening, rare pediatric chronic aging-related conditions Therapies for life-threatening, rare pediatric & chronic aging-related conditions POSITIVE REGULATORY 5 FDA LARGE U.S. CLINICAL DATA PATHWAY TO BLAs DESIGNATIONS MARKETS ➢ Encouraging data in 5 ➢ FDA Type C ➢ HLHS: Orpha
Slide 17: Cellular Therapy Laromestrocel (Lomecel B) -- A Pipeline in a Product
Cellular Therapy Laromestrocel (Lomecel BTM) --A Pipeline in a Product Cellular Therapy Laromestrocel (Lomecel BTM) -- A Pipeline in a Product • Stem cell therapy uses stem cells to repair, regenerate or replace damaged or diseased cells in the body • Allogeneic (donor-derived) mesenchymal stem cell
Slide 18: Laromestrocel -- A Pipeline in a Product
Laromestrocel -- A Pipeline in a Product Laromestrocel -- A Pipeline in a Product Global Patient Phase 1 Phase 2 Phase 3 Milestones Population • Ph2b enrollment completed, Top- Hypoplastic Left line data anticipated Sept 2026 > 30,0001 Heart Syndrome • Rare Pediatric Disease, Orphan Drug, Fast Track
Slide 19: Laromestrocel Multiple Potential Mechanisms of Action (MOA)
Laromestrocel Multiple Potential Mechanisms of Action (MOA) Laromestrocel Multiple Potential Mechanisms of Action (MOA) Pro-vascular, Pro-regenerative and Anti-inflammatory: Repairs Tissue and Promotes Healing Potential Anti-inflammatory Cell-cell Interactions Exosome and MicroRNA Mitochondrial Tran
Slide 20: Laromestrocel Potential Mechanisms of Action
Laromestrocel Potential Mechanisms of Action Laromestrocel Potential Mechanisms of Action Potential Mechanisms of Action These mechanisms support use in: ▪ Diseases with ▪ Pro-vascular/pro-endothelial endothelial dysfunction ▪ Anti-inflammatory ▪ Inflammation ▪ Anti-fibrotic ▪ Fibrosis ▪ Stimulate i
Slide 21: Laromestrocel for Hypoplastic Left Heart Syndrome (HLHS)
Laromestrocel for Hypoplastic Left Heart Syndrome (HLHS) Laromestrocel for Hypoplastic Left Heart Syndrome (HLHS)
Slide 22: Significant Unmet Need in HLHS
Significant Unmet Need in HLHS Significant Unmet Need in HLHS • Rare congenital heart defect: Univentricular malformation • Children with HLHS require 3 staged open- heart surgeries for survival • Even with surgery, survival to adolescence estimated at only 50% to 60%2 • 5 years transplant-free surv
Slide 23: Laromestrocel - a potential therapy for HLHS administered during the stage II Glenn surgery
Laromestrocel - a potential therapy for HLHS administered during the stage II Glenn surgery Laromestrocel administered into • Administration via RV during stage II surgery intramyocardial injection has been clinically shown to Glenn (St II @ ~4 mos): redirects blood to PA enhance cell retention and
Slide 24: Long-term Survival Data Presented at 2024 Congenital Heart Surgeon's Society Annual Meeting
Long-term Survival Data Presented at 2024 Congenital Heart Surgeon’s Society Annual Meeting ELPIS I - 100% transplant-free survival for 10 patients up to 5 years post Glenn surgery • ELPIS I met its primary endpoint of safety through 1-year post-treatment, with 100% survival rate, 100% transplant-fr
Slide 25: Long-term Survival in HLHS from ELPIS I Trial of laromestrocel
Long-term Survival in HLHS from ELPIS I Trial of laromestrocel Long-term Survival in HLHS from ELPIS I Trial of laromestrocel Post-Stage II Heart Transplant-Free 5-years Survival SVR patients matched with ELPIS I patient’s population (N=157) ELPIS I patient’s population (N=10) • 100% Transplant-free
Slide 26: ELPIS II: Phase 2b Study Design for HLHS
ELPIS II: Phase 2b Study Design for HLHS ELPIS II: Phase 2b Study Design for HLHS Injections During Stage II Surgery Post Surgical Follow-Up Clinical Screening Baseline (randomized, blinded) (day 5, week 4, month 6, month 12) N=20 Eligibility Criteria Group 1 Key Measures Assessed All participants m
Slide 27: Laromestrocel for Pediatric Dilated Cardiomyopathy (PDCM)
Laromestrocel for Pediatric Dilated Cardiomyopathy (PDCM) Laromestrocel for Pediatric Dilated Cardiomyopathy (PDCM)
Slide 28: Pediatric Dilated Cardiomyopathy (PDCM) - 2nd indication
Pediatric Dilated Cardiomyopathy (PDCM) - 2nd indication Pediatric Dilated Cardiomyopathy (PDCM) - 2nd indication • Pediatric Dilated Cardiomyopathy (PDCM) is a rare, progressive, life-threatening disease • ~40% of children with dilated cardiomyopathy require a heart transplant or die within two yea
Slide 29: Laromestrocel for PDCM
Laromestrocel for PDCM Laromestrocel for PDCM By reducing inflammation, inhibiting fibrosis, and promoting new blood vessel formation, laromestrocel may stop or reverse deterioration of heart function in PDCM. FDA supports an accelerated clinical laromestrocel development and regulatory pathway for
Slide 30: Laromestrocel for Alzheimer's Disease (AD)
Laromestrocel for Alzheimer’s Disease (AD) Laromestrocel for Alzheimer’s Disease (AD)
Slide 31: Laromestrocel for Alzheimer's Disease
Laromestrocel for Alzheimer’s Disease Laromestrocel for Alzheimer’s Disease Targeting CNS Inflammation • Previous therapies targeted amyloid plaques (b-secretase inhibitors and anti-amyloid antibodies) or neurofibrillary tangles (antibodies) with little evidence of disease state improvement • Inflam
Slide 32: CLEAR MIND Phase 2a Study Design
CLEAR MIND Phase 2a Study Design CLEAR MIND Phase 2a Study Design Screening 4 X Infusions Final Follow Up Baseline Weeks -6 -4 0 4 8 12 16 26 39 Study Begins Randomization 1:1:1:1 Percentage of patients with at least Primary Endpoint 1 SAE 4 weeks from any infusion Group 1: Placebo [N=12] Group 2: S
Slide 33: CLEAR MIND Phase 2a Results for Alzheimer's Disease
CLEAR MIND Phase 2a Results for Alzheimer’s Disease CLEAR MIND Phase 2a Results for Alzheimer’s Disease ▪ Trial results selected for featured research oral presentation at the 2024 Alzheimer's Association International Conference (AAIC) July 2024 ▪ Laromestrocel demonstrated positive benefit/risk pr
Slide 34: CLEAR MIND Phase 2a Conclusions and Pathway to BLA
CLEAR MIND Phase 2a Conclusions and Pathway to BLA CLEAR MIND Phase 2a Conclusions and Pathway to BLA ▪ Results of the CLEAR MIND clinical trial support the therapeutic potential of laromestrocel in the treatment of mild Alzheimer’s disease and provided evidence-based support for further clinical de
Slide 35: Laromestrocel for Aging-related Frailty (AF)
Laromestrocel for Aging-related Frailty (AF) Laromestrocel for Aging-related Frailty (AF)
Slide 36: Aging-related Frailty
Aging-related Frailty* Aging-related Frailty* Diminishing Health, Independence and QoL • Frailty Etiology of Aging-related Frailty ‒ Age-associated decline in reserve and function across multiple physiologic systems leading to inability to cope with stressors ‒ Characterized by mobility disability,
Slide 37: Laromestrocel for Aging-related Frailty
Laromestrocel for Aging-related Frailty Laromestrocel for Aging-related Frailty Completed U.S. Phase 2b Study Aging-related Frailty Study (N=143) • Designed to determine whether there was a dose response to a single infusion of laromestrocel in Aging-related Frailty Results: • There were 5 treatment
Slide 38: Financial Position
Financial Position Cash and cash equivalents: $10.1M Class A common stock outstanding: 28.2 M Class B common stock outstanding: 1.5 M Series A non-voting convertible preferred stock outstanding: 11,873 Shares of common stock exercisable under outstanding warrants: 21.2 M (as of 6/30/2026) 38
Slide 39: Longeveron Priorities for Next 12 Months
Longeveron Priorities for Next 12 Months Longeveron Priorities for Next 12 Months • Conclude data read-out of the ELPIS II clinical trial in HLHS and meet with FDA following read-out to determine path forward • Continue our partnership identification and evaluation efforts • Initiate enrollment in o
Slide 40: Experienced and Successful Leadership
Experienced and Successful Leadership Experienced and Successful Leadership Joshua Hare, MD Steve Willard Marie Washburn EXECUTIVE CHAIRMAN, CHIEF EXECUTIVE OFFICER CHIEF FINANCIAL OFFICER CO-FOUNDER & CHIEF SCIENCE OFFICER Paul Lehr Devin Blass Nataliya Agafonova, MD GENERAL COUNSEL & SECRETARY CHI
Slide 41: Thank You
Thank You Thank You Website www.longeveron.com Chief Executive Officer Steve Willard (703) 624- 8747 SWillard@longeveron.com Investor Relations Derek Cole Investor Relations Advisory Solutions derek.cole@IRadvisory.com Social Media Converge Miami 1951 NW 7th AVENUE Suite 520 @Longeveron Inc Miami, F